Cel-Sci Corporation (CVM): Price and Financial Metrics


Cel-Sci Corporation (CVM): $22.21

0.06 (+0.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CVM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

CVM POWR Grades


  • CVM scores best on the Growth dimension, with a Growth rank ahead of 62.22% of US stocks.
  • CVM's strongest trending metric is Stability; it's been moving down over the last 31 weeks.
  • CVM ranks lowest in Stability; there it ranks in the 4th percentile.

CVM Stock Summary

  • Cel Sci Corp's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 8.6% of US listed stocks.
  • CVM's price/sales ratio is 4,468.47; that's higher than the P/S ratio of 99.56% of US stocks.
  • Revenue growth over the past 12 months for Cel Sci Corp comes in at -65.92%, a number that bests just 4.15% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CVM, based on their financial statements, market capitalization, and price volatility, are TGTX, AQMS, FTFT, VHC, and NCTY.
  • Visit CVM's SEC page to see the company's official filings. To visit the company's web site, go to cel-sci.com.

CVM Stock Price Chart Interactive Chart >

Price chart for CVM

CVM Price/Volume Stats

Current price $22.21 52-week high $40.91
Prev. close $22.15 52-week low $10.76
Day low $21.36 Volume 718,500
Day high $22.45 Avg. volume 1,088,881
50-day MA $20.81 Dividend yield N/A
200-day MA $16.62 Market Cap 913.48M

Cel-Sci Corporation (CVM) Company Bio


CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.


CVM Latest News Stream


Event/Time News Detail
Loading, please wait...

CVM Latest Social Stream


Loading social stream, please wait...

View Full CVM Social Stream

Latest CVM News From Around the Web

Below are the latest news stories about Cel Sci Corp that investors may wish to consider to help them evaluate CVM as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investors!

William White on InvestorPlace | June 9, 2021

CEL-SCI Stock Drops After Raising $31.7M Via Secondary Equity Offering

CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at $22.62 per share representing a 5% discount to Tuesday's closing price of $23.82 per share. The offering is expected to close by June 11. Underwriters have an option to purchase up to 15% of the offering. The proceeds will be used to fund the continued development of the pipeline based on Multikine and LEAPS technologies and other general c

Yahoo | June 9, 2021

CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million

CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million.

Yahoo | June 9, 2021

CEL-SCI Announces Bought Deal Offering

CEL-SCI Announces Bought Deal Offering

Yahoo | June 8, 2021

Can You Count on This Popular Reddit Cancer-Treatment Stock?

Over the past year, shares of CEL-SCI (NYSEMKT: CVM), one of the most shorted companies in the biotech industry, have gone up 70% as the Reddit community r/WallStreetBets began speculating about its potential to launch a new head and neck cancer treatment. There is even a website called killcvmshorts.com with step-by-step instructions on orchestrating a squeeze against those betting on CEL-SCI's failure. At the same, Geert Kersten, the company's CEO, has been engaging in verbal showdowns with those who dare to criticize CEL-SCI's technology on Twitter.

Yahoo | June 5, 2021

Read More 'CVM' Stories Here

CVM Price Returns

1-mo -0.54%
3-mo 9.14%
6-mo 58.76%
1-year 71.90%
3-year 625.82%
5-year 85.08%
YTD 90.48%
2020 27.43%
2019 218.82%
2018 51.85%
2017 8.00%
2016 -81.08%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9622 seconds.